Barclays Maintains an 'Overweight' on Sequenom (SQNM); Q4 Review: T21 on Track, Cash Adequate
Tweet Send to a Friend
Barclays maintains an 'Overweight' on Sequenom (NASDAQ: SQNM), PT $9.
Barclays analyst says, "T21 test development on track for LDT ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "T21 test development on track for LDT ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
